Reviewing Odonate Therapeutics Inc. (ODT)’s and Synlogic Inc. (NASDAQ:SYBX)’s results

Odonate Therapeutics Inc. (NASDAQ:ODT) and Synlogic Inc. (NASDAQ:SYBX) compete with each other in the Biotechnology sector. We will analyze and compare their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Odonate Therapeutics Inc. 32 0.00 13.82M -4.46 0.00
Synlogic Inc. 2 0.00 16.49M -2.00 0.00

In table 1 we can see Odonate Therapeutics Inc. and Synlogic Inc.’s gross revenue, earnings per share and valuation.


Table 2 represents Odonate Therapeutics Inc. (NASDAQ:ODT) and Synlogic Inc. (NASDAQ:SYBX)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Odonate Therapeutics Inc. 42,549,261.08% -78% -68.4%
Synlogic Inc. 752,830,533.24% -38.9% -33.6%


Odonate Therapeutics Inc.’s Current Ratio is 9.6 while its Quick Ratio is 9.6. On the competitive side is, Synlogic Inc. which has a 11.5 Current Ratio and a 11.5 Quick Ratio. Synlogic Inc. is better positioned to pay off short and long-term obligations compared to Odonate Therapeutics Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Odonate Therapeutics Inc. and Synlogic Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Odonate Therapeutics Inc. 1 0 0 1.00
Synlogic Inc. 1 0 0 1.00

Odonate Therapeutics Inc.’s downside potential currently stands at -71.41% and an $10 consensus target price. On the other hand, Synlogic Inc.’s potential downside is -9.71% and its consensus target price is $2. Based on the data delivered earlier, Synlogic Inc. is looking more favorable than Odonate Therapeutics Inc., analysts view.

Institutional & Insider Ownership

The shares of both Odonate Therapeutics Inc. and Synlogic Inc. are owned by institutional investors at 83.5% and 82.8% respectively. About 0.1% of Odonate Therapeutics Inc.’s share are owned by insiders. Comparatively, 25.2% are Synlogic Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Odonate Therapeutics Inc. 21.28% 8.9% 135.96% 150.77% 100.89% 189.42%
Synlogic Inc. -9.95% -40.13% -35.81% -25.4% -39.74% -19.97%

For the past year Odonate Therapeutics Inc. had bullish trend while Synlogic Inc. had bearish trend.


Synlogic Inc. beats on 8 of the 10 factors Odonate Therapeutics Inc.

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Synlogic, Inc. develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.